CHICAGO — HemOnc Today Next Gen Innovator Michael S. Lee, MD, assistant professor of medicine at the University of North Carolina, Chapel Hill, and oncologist at the Lineberger Comprehensive Cancer Center, discusses two “key” abstracts in gastrointestinal cancer that were presented at the ASCO Annual Meeting.
The first study Lee reviews is a pooled analysis of four randomized trials that compared the outcomes of patients with high-risk, stage 2 colorectal cancer who received 3 vs. 6 months of adjuvant oxaliplatin-based chemotherapy. The second study he discusses is the phase 3 KEYNOTE-240 study, which compared pembrolizumab (Keytruda, Merck) with best supportive care for second-line therapy in patients with advanced hepatocellular carcinoma.
Finn RS, et al. Abstract 4004. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Iveson T, et al. Abstract 3501. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Lee reports no relevant financial disclosures.